CMS certification 420102
Prisma Health Patewood Hospital
175 Patewood Drive, Greenville, SC 29615
Prisma Health Patewood Hospital has a CMS overall rating of 5 out of 5 stars. 81% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 8 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none.
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 445 completed surveys, 11% response rate, Oct 2024 – Sep 2025.
How Prisma Health Patewood Hospital compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Prisma Health Patewood HospitalThis hospital | 5/5 | 81% | — | 1 better |
| Prisma Health Greenville Memorial HospitalSame city | 4/5 | 69% | 3 h 54 min | 6 better |
| St Francis-DowntownSame city | 4/5 | 77% | 2 h 43 min | 4 better 1 worse |
| Pelham Medical CenterSame county · Greer | 5/5 | 85% | 2 h 57 min | 1 better 1 worse |
| Prisma Health Hillcrest HospitalSame county · Simpsonville | 4/5 | 71% | 2 h 55 min | 1 better |
| Abbeville Area Medical CenterSame ZIP area · Abbeville | Not rated | 82% | 2 h 8 min | No different |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Greenville.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 145 cases | Too few cases | 4% | 3.9% |
6 more measures had too few cases here to report.
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 0.93 likely 0.43 – 1.43 | 1 |
| After hip or knee replacement 65 cases | Too few cases | 3.8% | 4.1% |
| Pressure ulcers (bed sores) 84 cases | No different | 0.59 per 1,000 likely 0 per 1,000 – 1.9 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 284 cases | No different | 0.21 per 1,000 likely 0 per 1,000 – 0.44 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 256 cases | No different | 0.26 per 1,000 likely 0.05 per 1,000 – 0.48 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 272 cases | No different | 2.26 per 1,000 likely 0.55 per 1,000 – 3.96 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 233 cases | No different | 1.64 per 1,000 likely 0 per 1,000 – 3.36 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 228 cases | No different | 8.34 per 1,000 likely 0 per 1,000 – 17.94 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 282 cases | No different | 3.16 per 1,000 likely 0.65 per 1,000 – 5.68 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 228 cases | No different | 4.99 per 1,000 likely 0.75 per 1,000 – 9.24 per 1,000 | 5.27 per 1,000 |
3 more measures had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| C. diff intestinal infections | No different | 0 | 1 |
5 more measures had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after hip or knee replacement 63 cases | Too few cases | 6.1% | 5.8% |
| Unplanned visits after an outpatient colonoscopy 1,252 cases | No different | 12.2 per 1,000 likely 9.3 per 1,000 – 16 per 1,000 | 13 per 1,000 |
| Unplanned visits after outpatient surgery 679 cases | No different | 0.8 likely 0.6 – 1.1 | — |
11 more measures had too few cases here to report.
Clinicians registered at this address
20 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Family | 5 |
| Hospitalist | 5 |
| Athletic Trainer | 3 |
| Pediatrics | 3 |
| Pharmacist | 2 |
| Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist | 1 |
| Registered Nurse | 1 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $122,182
- 2020 $225,202
- 2021 $1.1M
- 2022 $1.4M
- 2023 $1.9M
- 2024 $1.1M
- 2025 $1.1M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $629,334 | 5 |
| Space rental and facility fees | $6,000 | 3 |
| Debt forgiveness | $368 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Gilead Sciences, Inc. | $637,710 | 6 |
| AstraZeneca UK Limited | $111,519 | 3 |
| AstraZeneca Pharmaceuticals LP | $96,531 | 8 |
| Alexion Pharmaceuticals, Inc. | $78,071 | 1 |
| Medtronic, Inc. | $48,192 | 6 |
| Indivior Inc. | $33,241 | 33 |
| Ardelyx, Inc. | $31,476 | 13 |
| Kite Pharma, Inc. | $22,250 | 3 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| a phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult parti… Alexion Pharmaceuticals, Inc. | $78,071 |
| A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patient… AstraZeneca UK Limited | $64,201 |
| A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel… AstraZeneca UK Limited | $43,868 |
| EMBOLISE Medtronic, Inc. | $34,674 |
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of T… AstraZeneca Pharmaceuticals LP | $27,205 |
| A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREAT… Indivior Inc. · NCT04995029 | $25,649 |
| A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI… AstraZeneca Pharmaceuticals LP | $23,808 |
| A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line loc… AstraZeneca Pharmaceuticals LP | $22,850 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Prisma Health Patewood Hospital
Is Prisma Health Patewood Hospital a good hospital?
Prisma Health Patewood Hospital has a CMS overall rating of 5 out of 5 stars. Of the 8 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Prisma Health Patewood Hospital?
81% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 445 completed HCAHPS surveys.
Does Prisma Health Patewood Hospital have an emergency room?
No. CMS does not list emergency services at Prisma Health Patewood Hospital.
Does Prisma Health Patewood Hospital receive money from drug and device companies?
Drug and device makers reported $1.1M in payments to Prisma Health Patewood Hospital for 2025, under the federal Open Payments program. A payment on its own does not show a conflict of interest.